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Use of N-nitrosodimethylamine (NDMA) contaminated valsartan 
products and risk of cancer: Danish nationwide cohort study
Anton Pottegård,1 Kasper Bruun Kristensen,1 Martin Thomsen Ernst,1 Nanna Borup Johansen,2 
Pierre Quartarolo,3 Jesper Hallas1
ABSTRACT
Objective
To perform an expedited assessment of cancer risk 
associated with exposure to N-nitrosodimethylamine 
(NDMA) through contaminated valsartan products.
Design
Nationwide cohort study.
setting
Danish health registries on individual level prescription 
drug use, cancer occurrence, and hospital diagnoses.
ParticiPants
5150 Danish patients with no history of cancer, aged 
40 years or older, and using valsartan at 1 January 
2012 or initiating use between 1 January 2012 and 30 
June 2017. Participants were followed from one year 
after cohort entry (lag time period) until experiencing 
a cancer outcome, death, migration, or end of study 
period (30 June 2018). Each participant’s exposure 
to NDMA (ever exposure and predefined categories 
of cumulative valsartan exposure) was mapped out 
as a time varying variable while also applying a one 
year lag.
Main OutcOMe Measures
Association between NDMA exposure and a primary 
composite endpoint comprising all cancers except 
non-melanoma skin cancer, estimated using Cox 
regression. In supplementary analyses, the risk of 
individual cancers was determined.
results
The final cohort comprised 5150 people followed for a 
median of 4.6 years. In total, 3625 cohort participants 
contributed 7344 person years classified as unexposed 
to NDMA, and 3450 participants contributed 11 920 
person years classified as ever exposed to NDMA. 
With 104 cancer outcomes among NDMA unexposed 
participants and 198 among exposed participants, the 
adjusted hazard ratio for overall cancer was 1.09 (95% 
confidence interval 0.85 to 1.41), with no evidence 
of a dose-response relation (P=0.70). For single 
cancer outcomes, increases in risk were observed for 
colorectal cancer (hazard ratio 1.46, 95% confidence 
interval 0.79 to 2.73) and for uterine cancer (1.81, 
0.55 to 5.90), although with wide confidence intervals 
that included the null.
cOnclusiOns
The results do not imply a markedly increased short 
term overall risk of cancer in users of valsartan 
contaminated with NDMA. However, uncertainty 
persists about single cancer outcomes, and studies 
with longer follow-up are needed to assess long term 
cancer risk.
Introduction
Valsartan is an angiotensin II receptor antagonist used 
to treat hypertension and heart failure.1 2 In July 2018, 
some valsartan products were discovered to have been 
contaminated with N-nitrosodimethylamine (NDMA).3 
This contamination, which far exceeded regulatory 
exposure limits, was specific to drug products 
manufactured by Zhejiang Huahai Pharmaceuticals, 
a company in Linhai, China, and seems to be related 
to a change in the manufacturing process that was 
implemented in 2012. Consequently, medical agencies 
across Europe as well as the US Food and Drug 
Administration have withdrawn all affected valsartan 
products from the market as of July 2018.3
NDMA is the simplest dialkylnitrosamine and is 
known to be a by-product in various industries—for 
example, the manufacture of pesticides, rubber tyres, 
alkylamines, and dyes.4 NDMA is one of the most well 
characterised and most potent animal carcinogens 
known and has been shown to be a potent carcinogen 
across all species that have been investigated, both 
as single doses and with long term exposure to lower 
quantities.5 Although no in vivo data are available for 
humans, NDMA seems to be metabolised similarly in 
human tissue and rodent tissue.6 The International 
Agency for Research on Cancer (IARC) has on this 
basis classified NDMA as “probably carcinogenic 
to humans” (group 2A), emphasising that NDMA 
“should be regarded for practical purposes as if it were 
carcinogenic to humans.”7
We accessed the nationwide Danish healthcare 
registries and conducted an expedited observational 
cohort study of the association between use of 
potentially NDMA contaminated valsartan products 
and risk of cancer. Our aim was to quantify the potential 
consequences of NDMA contaminated drug products 
entering the market and to provide timely information 
for regulatory bodies evaluating this potential public 
health issue.
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WhAT IS AlReAdy knoWn on ThIS TopIC
Some valsartan products are suspected of having been contaminated with 
N-nitrosodimethylamine (NDMA), which is classified as carcinogenic to humans
After the discovery, European medical agencies and the US Food and Drug 
Administration withdrew affected valsartan products from the market
WhAT ThIS STudy AddS
Among Danish valsartan users, exposure to NDMA contaminated valsartan was 
not associated with a markedly increased risk of overall cancer (adjusted hazard 
ratio 1.09, 95% confidence interval 0.85 to 1.41)
Future studies are, however, required to evaluate the risks for single cancer 
outcomes as well as long term effects
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Methods
We conducted a cohort study comparing cancer 
outcomes in users of potentially NDMA contaminated 
valsartan products with users of valsartan products 
assumed free from this contaminant.
Data sources and linkage
We obtained data from four Danish nationwide 
registries: the Danish Cancer Registry,8 9 the National 
Prescription Registry,10 the National Patient Register,11 
and the Civil Registration System.12 Supplementary 
appendix A describes the data sources in detail and 
appendix B provides the codes for cancer diagnoses, 
drug exposures, and covariates. Data were linked by 
the personal identification number, a unique identifier 
assigned to all Danish residents since 1968.13 Virtually 
all medical care in Denmark is provided by the national 
health authorities, allowing population based register 
linkage studies covering all legal residents of Denmark.
study cohort
The study cohort comprised all Danish patients filling 
a valsartan prescription during the study period of 
1 January 2012 to 30 June 2018. Prevalent users of 
valsartan at the start of the study period—defined as 
individuals having filled a valsartan prescription in 
September to the end of December 2011, entered the 
study cohort at 1 January 2012, whereas incident 
users entered the study cohort at the day of filling their 
first valsartan prescription during the study period. 
As patients contributed risk time from one year after 
entering the study cohort, we excluded those with less 
than one year of follow-up, as they did not contribute to 
any of the analyses reported. For the same reason, we 
excluded incident users filling their first prescription 
after 30 June 2017. We further excluded patients with a 
record of a previous cancer except non-melanoma skin 
cancer; those with a recent migration before cohort 
entry (within two years) to ensure enough baseline 
data on all study participants; and those aged less than 
40 years at cohort entry as both use of valsartan and 
cancer occurrence is rare among children and younger 
adults. Participants were followed until a cancer 
outcome, death, migration, or end of the study period 
(30 June 2018), whichever occurred first.
ascertainment of nDMa exposure
Within the study cohort we mapped out each 
participant’s exposure to NDMA contamination using 
the unique drug ID (Nordic article number) as recorded 
in the National Prescription Registry to identify the 
single valsartan product and its manufacturer. From 
the 128 unique valsartan drug products used during 
2012-18 within our study population, we identified 
18 drug products (which constituted 18% of all 
prescriptions filled) that were manufactured using 
an active pharmaceutical ingredient from Zhejiang 
Huahai Pharmaceuticals. These drug products were 
classified as probably contaminated with NDMA. An 
additional 36 drug products (26% of all prescriptions) 
were classified as possibly contaminated with NDMA, 
as they contained an active pharmaceutical ingredient 
both from Zhejiang Huahai Pharmaceuticals and from 
other companies. Seventy four drug products (55% 
of all prescriptions) were classified as unlikely to be 
contaminated with NDMA as they did not contain 
an active pharmaceutical ingredient from Zhejiang 
Huahai Pharmaceuticals. In the main analysis we 
pooled together valsartan prescriptions classified as 
probably and possibly contaminated with NDMA, 
classifying those filling such prescriptions as ever 
exposed to NDMA from their first occurrence of 
such a prescription. We further stratified NDMA 
exposed person time by cumulative dose from 
filled prescriptions of potentially NDMA containing 
valsartan tablets (applying preplanned stratums of 
<20 000, 20 000-49 999, and ≥50 000 mg). The use 
of milligrams of valsartan as a scale for the dose-
response analysis was based on the observation that 
the NDMA content for each tablet seems to correlate 
with the strength of the tablet.14 With an estimated 
daily use of 80-160 mg (the defined daily dose of 
valsartan is 80 mg15), these cut-offs corresponded 
roughly to <200, 200-499, and ≥500 tablets. Of note, 
individuals classified as exposed to NDMA contributed 
follow-up to the non-exposed cohort until filling their 
first prescription for a potentially NDMA contaminated 
product. This ensured that the estimates were not 
affected by immortal time bias.16
Throughout all assessments of potential exposure 
to NDMA, we applied a one year lag time—that is, 
persons contributed NDMA exposed person time from 
one year after having filled their first prescription for 
a potentially NDMA containing valsartan product and 
onwards. This was done as very recent NDMA exposure 
(<1 year) is considered unlikely to materially affect 
an individual’s risk of receiving a cancer diagnosis.17 
The length of the lag time was subjected to sensitivity 
analyses.
cancer outcomes
We obtained cancer outcomes from the Danish Cancer 
Registry.8 9 However, as data in this registry is currently 
only updated to 2016, we used the Danish National 
Patient Registry11 to ascertain outcomes from 1 January 
2017 to 30 June 2018. The primary outcome was a 
composite endpoint comprising all cancers (except 
non-melanoma skin cancer), as NDMA exposure is 
suspected to increase the risk of several different 
cancers. In supplementary analyses, we determined 
the risk of individual cancers, grouping cancers by 
organ system (ie, using codes from the international 
classification of diseases, 10th revision).
covariates
The study cohort was described according to several 
characteristics that were also incorporated as 
covariates in the analyses: use of drugs (prescription 
fill <120 days before cohort entry) known or suspected 
to affect cancer risk, including low dose aspirin, non-
aspirin non-steroidal anti-inflammatory drugs, 5-α 
reductase inhibitors, statins, spironolactone, oral 
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steroids, hormone replacement therapy, and selective 
serotonin reuptake inhibitors18; prior diagnoses 
(within five years from cohort entry) of diabetes, 
chronic obstructive pulmonary disease, heart failure, 
and alcohol related disease; Charlson comorbidity 
index scores (0, low; 1-2, medium; or ≥3, high; based 
on diagnoses established within the past five years 
before cohort entry)19 20; and whether the participant 
was a prevalent valsartan user at the beginning of the 
study period or initiated valsartan during the study 
period.
Main analysis
The primary analysis comprised a comparison of 
cancer occurrence during follow-up exposed to NDMA 
versus follow-up not exposed to NDMA. We used Cox 
regression to estimate the hazard ratio with 95% 
confidence intervals for cancer associated with NDMA 
exposure, both for ever use and for the predefined 
categories of cumulative use. The proportional hazards 
assumption was tested using Schoenfeld residuals. We 
carried out a formal dose-response test by categorising 
cumulative exposure to NDMA contaminated valsartan 
in categories of 10 000 mg as a time varying exposure 
and obtaining the P value for this variable as a 
continuous predictor of cancer risk in a Cox regression. 
As all comparisons were performed within users of 
valsartan, the exposure to NDMA can reasonably be 
expected to be a random event, and confounding is 
thus expected to be limited. Analyses were, however, 
performed as crude comparisons adjusted only for sex 
and age (age at cohort entry as continuous variable) 
as well as adjusted for sex, age, and the potential 
confounding factors. All analyses were performed 
using STATA Release 15.2.
sensitivity and supplementary analyses
We carried out several sensitivity and supplementary 
analyses. Firstly, we performed analyses stratifying 
all participants by sex and age (40-69 and ≥70 years 
at cohort entry). Secondly, we restricted the cohort to 
prevalent valsartan users at the start of the study and 
to incident users during the study period. Thirdly, 
we restricted the ascertainment of NDMA exposure 
to prescriptions classified as probably contaminated 
with NDMA, while censoring individuals filling a 
prescription for a possibly NDMA contaminated drug 
product from the reference cohort (although allowing 
them to later enter the NDMA exposed cohort). Lastly, 
we varied the one year lag time period applied in the 
main analysis to six months and two years.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing of results. There 
are no plans to disseminate the results of the research 
directly to the patient community. However, the results 
will be included in the ongoing review of the potential 
impact of NDMA contaminated valsartan on patients 
by the European Medicines Agency.
Results
In initial descriptive analyses, we identified 7068 
unique individuals filling a total of 95 650 valsartan 
prescriptions from January 2012 to June 2018, the 
period where NDMA contaminated products were 
on the Danish market. The overall use of valsartan 
increased slightly during this period, in particular 
in 2017 and 2018 (fig 1), and the use of valsartan 
products possibly or probably contaminated with 
NDMA constituted about half of the total valsartan 
use, although this proportion dropped slightly during 
2017-18.
For the selection of the study cohort, we identified 
6406 individuals filling a valsartan prescription 
between September 2011 and June 2017. Of these, 
5150 unique individuals met our inclusion criteria 
and entered the final cohort (fig 2), contributing a 
median of 4.6 years (interquartile range 2.0-5.5 years) 
of follow-up to the analysis, after the application of 
a one year lag period. Table 1 includes the baseline 
characteristics of valsartan users entering the study. 
A total of 3625 participants contributed 7344 person 
years of follow-up classified as unexposed to NDMA, 
and 3450 participants contributed 11 920 person 
years classified as ever exposed to NDMA (fig 2). 
The distribution of potentially NDMA contaminated 
and non-contaminated prescriptions were similar 
between the study cohort and all valsartan users (see 
supplementary figure 1).
Overall, exposure to potentially (probably or 
possibly) NDMA contaminated valsartan products 
showed no association with cancer compared 
with exposure to valsartan products unlikely to be 
contaminated with NDMA (adjusted hazard ratio 1.09, 
95% confidence interval 0.85 to 1.41) and no evidence 
of a dose-response relation (P=0.70, table 2).
Year
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g)
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200
Probably NDMA contaminated
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Unlikely NDMA contaminated
Fig 1 | use of valsartan in kilograms of active 
substance, specified by drug products classified as 
probably, possibly, or unlikely to be contaminated with 
n-nitrosodimethylamine (nDMa). the drop in 2018 
results from data only being available to june 2018
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In analyses of single cancer outcomes, increased 
risks were seen for colorectal cancer (hazard ratio 1.46, 
95% confidence interval 0.79 to 2.73) and for uterine 
cancer (1.81, 0.55 to 5.90), although neither these 
nor other single cancer outcomes reached statistical 
significance (fig 3). Analyses of other cancer outcomes 
were not possible owing to low numbers—that is, no 
cancer outcomes outside those included in figure 3 
showed any associations with NDMA use.
Results comparable to the main analyses were 
found when we stratified by sex and age, whereas a 
stronger association was seen when we restricted to 
incident users during the study period (hazard ratio 
1.58, 95% confidence interval 0.99 to 2.52) compared 
with prevalent users at the beginning of the study 
period (0.91, 0.66 to 1.25) (fig 4). A test for interaction 
between being an incident valsartan user and the 
effect of exposure to NDMA yielded a p value of 0.059.
The sensitivity analysis censoring individuals filling 
a prescription for a possibly NDMA contaminated 
valsartan product from the reference category yielded 
results comparable to those of the main analyses, both 
for overall cancer (see supplementary table 1) and for 
single cancers (see supplementary figure 2).
Varying the lag time from one year used in the main 
analyses to six months or two years yielded slightly 
higher risk estimates with increasing lag time, with 
the hazard ratio for ever exposure increasing to 1.17 
(95% confidence interval 0.88 to 1.55) when a two 
year lag time was applied, although this did not reach 
statistical significance (see supplementary table 2).
discussion
In this nationwide cohort study of Danish valsartan 
users, we did not see an increased short term 
overall risk of cancer associated with the use of 
valsartan products potentially contaminated with 
N-nitrosodimethylamine (NDMA).
All valsartan users (n=6406)
Total cohort (n=5150)
NDMA exposed (n=3450,
11 920 person years)
NDMA unexposed (n=3625,
7344 person years)
Excluded (n=1256):
  Previous cancer (n=629)
  Recent migration (n=334)
  Age <40 years (n=98)
  <1 year follow-up (n=195)
Fig 2 | Flowchart of cohort selection of Danish users 
of valsartan, january 2012 to june 2018. nDMa=n-
nitrosodimethylamine
table 1 | baseline characteristics of valsartan users entering study and among those potentially exposed and not 
exposed to n-nitrosodimethylamine (nDMa)
characteristics all (n=5150) nDMa exposure
exposed* (n=3450) not exposed* (n=3625)
Sex:
 Men 2531 (49.1) 1630 (46.9) 1745 (43.6)
 Women 2619 (50.9) 1820 (53.1) 1880 (56.4)
Age (years):
 Median (interquartile range) 66 (58-74) - -
 40-69 3195 (62.0) 2197 (65.0) 2164 (61.2)
 ≥70 1955 (38.0) 1253 (35.0) 1461 (38.8)
Prevalent valsartan users†:
 No 2870 (55.7) 2012 (51.2) 1353 (25.7)
 Yes 2280 (44.3) 1438 (48.8) 2272 (74.3)
Charlson comorbidity score:
 0 (low) 3864 (75.0) 2697 (79.0) 2635 (74.9)
 1 884 (17.2) 541 (15.3) 670 (17.1)
 2 217 (4.2) 117 (3.2) 168 (4.5)
 ≥3 (high) 185 (3.6) 95 (2.5) 152 (3.4)
Drugs:
 Low dose aspirin 1388 (27.0) 842 (25.2) 1092 (29.2)
 Non-aspirin NSAID 772 (15.0) 533 (15.5) 513 (16.0)
 Statins 1924 (37.4) 1185 (35.1) 1457 (37.4)
 Spironolactone 405 (7.9) 117 (3.2) 362 (4.9)
 Glucocorticoids for systemic use 244 (4.7) 166 (4.5) 171 (4.3)
 5-α reductase inhibitors 64 (1.2) 41 (1.2) 47 (0.9)
 SSRIs 299 (5.8) 196 (5.7) 223 (6.0)
 Hormone replacement therapy 454 (8.8) 319 (9.8) 338 (9.9)
Diagnoses:
 Diabetes type 1 and 2 899 (17.5) 559 (16.1) 667 (18.0)
  Chronic obstructive pulmonary disease 247 (4.8) 131 (3.5) 200 (4.3)
 Congestive heart failure 535 (10.4) 117 (2.9) 497 (5.3)
 Alcohol related disease 48 (0.9) 28 (0.7) 34 (0.7)
NSAID=non-steroidal anti-inflammatory drug; SSRIs=selective serotonin reuptake inhibitors.
*Characteristics weighted by proportion of total time exposed or not exposed that individuals contributed, thereby providing the distribution of covariates 
in the main analysis comparison.
†Defined as being included in the study at 1 January 2012 by having filled a valsartan prescription between September and December 2011.
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strengths and limitations of this study
The principal strength of this study is the use of 
high quality nationwide registries,9  10  11 leaving little 
potential for selection bias.12 Furthermore, the use of 
dispensing data, instead of data on prescribed drugs, 
as a proxy for NDMA exposure reduces the risk of 
misclassification due to primary non-adherence.21 
The principal weakness of the study is the limited 
median follow-up. Our findings only pertain to early 
cancer risk after exposure to NDMA whereas future 
studies are needed to elucidate the total cancer risk, 
which requires a substantially longer follow-up 
for the individual than what is currently available. 
Additionally, the limited follow-up combined with 
the low use of valsartan in Denmark leads to limited 
precision. Lastly, our exposure ascertainment is based 
on assumptions about NDMA content. Reassuringly, 
our sensitivity analysis disregarding less certain 
sources of NDMA returned estimates comparable to 
those of the main analysis. However, future studies 
should utilise data on the actual NDMA content of 
individual valsartan tablets once such information 
becomes available.
biological rationale
The International Agency for Research on 
Cancer (IARC) has classified NDMA as “probably 
carcinogenic to humans” owing to limited evidence of 
carcinogenicity in humans and sufficient evidence of 
carcinogenicity in animal studies.7 NDMA is suspected 
to have both localised and systemic carcinogenic 
effects due to the induction of DNA-damaging 
metabolites in the gastrointestinal tract and liver.6  22 
Specifically, in the liver, NDMA is metabolised by 
CYP2E1 to methyldiazonium, which causes mutations 
by methylation.23 Also, N-nitroso compounds such as 
NDMA activate ras oncogenes, which are thought to 
play a role in the development of colon cancer.6 As such, 
tumours in the gastrointestinal tract, lungs, kidneys, 
and liver have been seen in animal studies.5  23  24 
Evidence of carcinogenicity in rats was found at 
doses of about 10 µg/kg/day.23 With concentrations 
of up to 22 µg NDMA in 320 mg valsartan tablets and 
10 µg NDMA in 160 mg tablets,14 the daily exposure 
for a 70 kg person ranges from 0.14 to 0.31 µg/kg/
day. Even though it is not possible to extrapolate 
directly from animals to humans, the daily exposure 
in humans is thus roughly 30 times lower than the 
lowest dose leading to liver cancer in rats. Owing to 
the known carcinogenic effect of NDMA in animals, 
table 2 | estimates for association between use of valsartan products potentially contaminated with 
n-nitrosodimethylamine (nDMa) and cancer risk compared with non-contaminated valsartan products
nDMa exposure
Follow-up 
(person years)
cancer 
outcomes
incidence rate  
(/1000 person years)
adjusted hazard ratio* 
(95% ci)
Fully adjusted hazard 
ratio† (95% ci)
Never use 7344 104 14.2 1.00 (ref) 1.00 (ref)
Ever exposure 11 920 198 16.6 1.16 (0.91 to 1.49) 1.09 (0.85 to 1.41)
Cumulative exposure (mg)‡:
 <20 000 3776 67 17.7 1.26 (0.92 to 1.72) 1.15 (0.83 to 1.59)
 20000-49 999 2836 44 15.5 1.07 (0.75 to 1.53) 0.99 (0.69 to 1.43)
 ≥50 000 5308 87 16.4 1.14 (0.84 to 1.54) 1.11 (0.82 to 1.50)
Test for trend§ P=0.65 P=0.70
*Adjusted for age and sex.
†Adjusted for sex, age, use of low dose aspirin, non-aspirin non-steroidal anti-inflammatory drugs, 5-α reductase inhibitors, statins, spironolactone, oral 
steroids, hormone replacement therapy, or selective serotonin reuptake inhibitors, history of diabetes, chronic obstructive pulmonary disease, heart 
failure, or alcohol related disease, Charlson comorbidity index score, and being a prevalent valsartan user. 
‡Defined by total amount of NDMA contaminated valsartan filled.
§Estimated using Cox regression across 10 000 mg stratums of NDMA contaminated valsartan filled.
All cancers
Colorectal
Pancreatic
Lung
Melanoma
Breast
Uterine
Prostate
Kidney
Bladder
1.09 (0.85 to 1.41)
1.46 (0.79 to 2.73)
0.71 (0.21 to 2.44)
0.94 (0.47 to 1.91)
1.34 (0.46 to 3.85)
0.85 (0.42 to 1.73)
1.81 (0.55 to 5.90)
1.33 (0.68 to 2.62)
1.00 (0.22 to 4.65)
0.66 (0.15 to 2.89)
302
51
12
39
17
36
15
47
8
8
0.1 0.50.2 1 42 6
Cancer type Hazard ratio
(adjusted) (95% CI)
Hazard ratio
(adjusted) (95% CI)
No of
events
Fig 3 | estimates for association between use 
of potentially n-nitrosodimethylamine (nDMa) 
contaminated valsartan products and risk of single 
cancer outcomes compared with users of non-
contaminated valsartan products. number of events are 
total number of events among valsartan users
Sex
  Men
  Women
Age (years)
  <70
  ≥70
Prevalent user
  No
  Yes
0.96 (0.68 to 1.37)
1.27 (0.88 to 1.83)
1.00 (0.70 to 1.44)
1.16 (0.82 to 1.66)
1.58 (0.99 to 2.52)
0.91 (0.66 to 1.25)
154
148
151
151
138
164
0.5 1 3
Subgroups Hazard ratio
(adjusted) (95% CI)
Hazard ratio
(adjusted) (95% CI)
No of
events
2
Fig 4 | estimates for association between use 
of potentially n-nitrosodimethylamine (nDMa) 
contaminated valsartan products and cancer risk 
compared with users of non-contaminated valsartan 
products, specified by patient subgroups. number of 
events are total number of events among valsartan users
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no experimental studies in humans exist. However, as 
some dietary products (eg, processed meat) are known 
to contain small amounts of NDMA, epidemiological 
studies based on food frequency questionnaire data 
have been performed. Even though such studies are 
highly prone to confounding, three found an increased 
risk of gastrointestinal cancer with exposure to NDMA, 
predominantly colorectal cancer.25  26  27 This finding, 
together with that from the animal studies, provides 
some support for the increased although statistically 
non-significant risk for this particular cancer observed 
in our study. Only one previous paper has reported 
on uterine cancer, finding no association between 
exposure to NDMA and uterine cancer in rats.28 Lastly, 
no estimates could be obtained for liver cancer in 
our study owing to the absence of liver cancer events 
among those exposed to NDMA. A markedly increased 
risk of liver cancer associated with NDMA exposure 
thus seems unlikely.
Principal findings
Our estimates pertain to early cancer risk associated 
with exposure to NDMA through contaminated 
valsartan products and should not be interpreted as 
evidence against NDMA being carcinogenic to humans 
in general. At most, our findings suggest that the 
levels of NDMA exposure achieved through valsartan 
products do not translate into a substantially increased 
short term cancer risk. Furthermore, the fact that our 
study evaluates a potential safety concern holds 
some implications about how to interpret the results. 
While the estimate for our primary outcome suggests 
a negligible and statistically non-significant increase 
in cancer risk of 9%, it might be argued that a more 
cautious interpretation, reflecting the nature of the 
study question, would be to consider the upper limit of 
the confidence interval. Doing so leads to the different, 
although related, conclusion that we can reasonably 
exclude a more than 40% increased short term risk of 
cancer from exposure to NDMA contaminated valsartan 
products. A similar interpretation of the estimates 
obtained for the single cancer outcomes—in particular 
colorectal and uterine cancer—clearly highlights that 
our study cannot confidently rule out an increased risk 
from exposure to NDMA.
The finding that exposure to NDMA was associated 
with an increased risk of cancer specifically among 
users initiating valsartan treatment during the study 
period, as opposed to among valsartan users prevalent 
at the beginning of the study period, was a surprising 
finding that we cannot explain. The duration of follow-
up was on average longer for prevalent users, as they 
were followed from the beginning of the study period 
(1 January 2012), and a late effect of exposure to NDMA 
therefore cannot explain this finding, as it would have 
led to an increased risk specifically among prevalent 
and not incident valsartan users. Considering the 
uncertainty about the actual NDMA content of 
valsartan products, it could be speculated that those 
using valsartan later in the study period might have 
been exposed to NDMA more often. However, no data 
are available that can be used to test this hypothesis. 
Lastly, our subgroup analyses had limited power and 
therefore the possibility of our results being a chance 
finding should also be considered.
Policy implications
Our findings can support regulators in their evaluation 
of the potential public health impact of exposure 
to NDMA through valsartan products. The Danish 
nationwide health registries and the strong research 
infrastructure hosted by Statistics Denmark and the 
Danish Health Data Authority, the latter of which was 
used in this study, gives researchers and regulators 
a unique possibility to provide answers to such 
emerging public health concerns in a timely manner. 
The present analysis was completed and submitted 
for publication within seven weeks after the finding of 
NDMA in valsartan products was announced publicly, 
and the paper published in The BMJ after a fast track 
peer review process spanning only three weeks from 
submission to publication. We previously performed 
a similar expedited assessment of a putative bleeding 
risk associated with use of generic warfarin,29  30 
although its publication was delayed by the peer 
review process for several months. Besides rapid peer 
review assessment, a close collaboration between 
researchers and regulators is a key element in ensuring 
both speed and relevance of such research projects. 
In addition to knowledge about the risks associated 
with exposure to NDMA, the present study provides 
proof-of-concept for such processes, which hold great 
promise for the use of pharmacoepidemiological 
input in the regulatory assessment of future public 
health crises.
conclusion
We have assessed the potential cancer risk associated 
with exposure to NDMA through contaminated 
valsartan products and found no evidence of a markedly 
increased short term overall risk of cancer. However, 
we cannot exclude a modest association. Furthermore, 
owing to the limited follow-up, assessment of long 
term effects was not possible, and the low number of 
events makes interpretation of estimates for single 
cancer outcomes difficult. Therefore, further studies 
are needed to fully elucidate the health effects of 
NDMA contaminated valsartan products.
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